In the study, researchers demonstrated that small molecule ALK inhibitors, initially developed for sporadic neuroblastoma with non-inherited ALK mutations, could be even more effectively implemented ...

Datroway shows promising antitumor activity in advanced NSCLC with EGFR mutations and ALK rearrangements, achieving a 35.8% overall response rate. The treatment maintains a manageable safety profile, ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy. On July 21, Nuvalent announced that the first patient had been dosed in ALKAZAR, which is its global Phase 3 randomized, ...